Toshihiro Inoue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toshihiro Inoue has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Hiroo Takeda
Pharmacology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Azumino 399-8304, Japan
2 shared publicationsMamoru Kobayashi
Discovery Research Department, R&D, Kissei Pharmaceutical Co., Ltd., Azumino 399-8204, Japan
2 shared publicationsAyaka Yokoyama
Pharmacology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Nagano, Japan
1 shared publicationHironori Nishibe
Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Osaka 541-0045, Japan
1 shared publicationKazuma Ojima
Pharmacology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Nagano, Japan
1 shared publication- Kenji Akahane
Pharmacology Research Group, Pharmacology and Pharmacokinetics Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Nagano, Japan
1 shared publication
Latest Publications
- 1 July 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 806, 25-31
Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation
- 1 July 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 806, 25-31
Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation
- 9 May 2017
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 67 (07) , 396-403
Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes
We compared the individual effects of mitiglinide and glibenclamide administered in combination with the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin on plasma DPP-IV activity and blood glucose levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes (STZ-NA rats). We examined the inhibitory activity of mitiglinide and glibenclamide as well as their combination with sitagliptin on plasma DPP-IV activity in STZ-NA rats. The oral glucose tolerance test (OGTT) was used to compare effects of mitiglinide, glibenclamide, and their combination with sitagliptin on blood glucose levels in STZ-NA rats. Mitiglinide and glibenclamide did not inhibit rat DPP-IV and did not influence the inhibitory effect of sitagliptin on rat plasma DPP-IV activity. In STZ-NA rats, plasma glucose levels were stronger suppressed by a combination of mitiglinide and sitagliptin than by either drug used alone. However, no clear effect of the combination of glibenclamide and sitagliptin was observed. These results indicate that the combination of mitiglinide and sitagliptin has a lower risk of hypoglycemia in the rats with induced type 2 diabetes compared with the combination of glibenclamide and sitagliptin. The combination of mitiglinide and sitagliptin can be a promising combination for the treatment of diabetic patients.
- 9 May 2017
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 67 (07) , 396-403
Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes
We compared the individual effects of mitiglinide and glibenclamide administered in combination with the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin on plasma DPP-IV activity and blood glucose levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes (STZ-NA rats). We examined the inhibitory activity of mitiglinide and glibenclamide as well as their combination with sitagliptin on plasma DPP-IV activity in STZ-NA rats. The oral glucose tolerance test (OGTT) was used to compare effects of mitiglinide, glibenclamide, and their combination with sitagliptin on blood glucose levels in STZ-NA rats. Mitiglinide and glibenclamide did not inhibit rat DPP-IV and did not influence the inhibitory effect of sitagliptin on rat plasma DPP-IV activity. In STZ-NA rats, plasma glucose levels were stronger suppressed by a combination of mitiglinide and sitagliptin than by either drug used alone. However, no clear effect of the combination of glibenclamide and sitagliptin was observed. These results indicate that the combination of mitiglinide and sitagliptin has a lower risk of hypoglycemia in the rats with induced type 2 diabetes compared with the combination of glibenclamide and sitagliptin. The combination of mitiglinide and sitagliptin can be a promising combination for the treatment of diabetic patients.